Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 5/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | DRD4 | P21917 | 3/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MLNR | O43193 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HLA-A | P04439 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8294178 | 0.92 | KCNH2 (0.39) | KCNH2NR4A2DRD2HTR1ADRD4 | |
| SCHEMBL8294759 | 0.89 | KCNH2 (0.41) | KCNH2NR4A2JAK2JAK1DRD2 | |
| SCHEMBL8294179 | 0.86 | SSTR5 (0.47) | KCNH2NR4A2DRD2HTR1ADRD4 | |
| SCHEMBL8284395 | 0.85 | KCNH2 (0.41) | KCNH2NR4A2DRD2HTR1ADRD4 | |
| SCHEMBL14271789 | 0.85 | KCNH2 (0.41) | KCNH2NR4A2DRD2HTR1ADRD4 | |
| SCHEMBL8293630 | 0.85 | KCNH2 (0.39) | KCNH2NR4A2DRD2HTR1ADRD4 | |
| SCHEMBL8294757 | 0.84 | KCNH2 (0.39) | KCNH2NR4A2DRD2HTR1ADRD4 | |
| SCHEMBL8294931 | 0.83 | SSTR5 (0.37) | KCNH2NR4A2DRD2HTR1ADRD4 | |
| SCHEMBL12851974 | 0.82 | KCNH2 (0.39) | KCNH2NR4A2DRD2HTR1ADRD4 | |
| SCHEMBL14173547 | 0.82 | DRD2 (0.42) | KCNH2NR4A2JAK2JAK1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278455-B2 | 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | disclosed |
| US-8278455-B2 | 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | disclosed |
| US-20090062278-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | JANSSEN SCIENCES IRELAND UC (IE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062278-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | JANSSEN SCIENCES IRELAND UC (IE) | 2009-03-05 | — | — | US | disclosed |
| US-20070093502-A1 | 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | BONFANTI JEAN-FRANCOIS | 2007-04-26 | — | — | US | disclosed |
| US-20070093502-A1 | 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | BONFANTI JEAN-FRANCOIS | 2007-04-26 | — | — | US | disclosed |
| WO-2005058874-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093502-A1 | 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SUB1, HYOU1 | KCNH2 368/4885NR4A2 331/4885JAK2 661/4885 |
| US-20090062278-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYC1, SUB1 | KCNH2 419/4885NR4A2 400/4885JAK2 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.